New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.
The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?
A day after Lilly’s strong clinical showing in obesity, Novo comes out swinging.
But pressure is on the shingles vaccine as the consumer spin-off approaches.